Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12610000806066
Ethics application status
Approved
Date submitted
17/09/2010
Date registered
27/09/2010
Date last updated
15/06/2011
Type of registration
Retrospectively registered

Titles & IDs
Public title
Enoxaparin compared to Warfarin for the treatment of calf vein blood clots
Scientific title
Randomised open label trial assessing the frequency of receiving therapeutic anticoagulant dosing in 6 weeks of enoxaparin treatment compared with 6 weeks of warfarin treatment, for treatment of symptomatic isolated calf vein thrombosis
Secondary ID [1] 252714 0
Centre for Thrombotic and Bleeding Disorders Research Study Number: CTBR-009
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Calf Deep Vein Thrombosis 258204 0
Condition category
Condition code
Blood 258384 258384 0 0
Clotting disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
At least 6 weeks with subcutaneous enoxaparin only, dosage 1.5mg/kg daily. Duration of treatment will be determined by the treating physician in accordance with American College of Chest Physicians (ACCP) and National Health and Medical Research Council (NHMRC) Guidelines with consideration of individual patient clinical profile and risk factors and the results of follow up ultrasound. Most patients will receive treatment for three months.
Intervention code [1] 257221 0
Treatment: Drugs
Comparator / control treatment
Usual care: subcutaneous enoxaparin injections dosage 1.5mg/kg daily commenced immediately after diagnosis and commencing oral warfarin within a couple of days. Warfarin doses will be adjusted according to International Normalised Ratio (INR) blood tests. Once INR is in the range of 2.0 to 3.0 (usually 5 to 10 days) enoxaparin will be ceased and warfarin continues for at least 6 weeks. Warfarin dosage will be individualised for each patient and is expected to be within the range of 1mg-10mg per oral daily.
Duration of treatment will be determined by the treating physician in accordance with American College of Chest Physicians (ACCP) and National Health and Medical Research Council (NHMRC) Guidelines with consideration of individual patient clinical profile and risk factors and the results of follow up ultrasound. Most patients will receive treatment for three months.
Control group
Active

Outcomes
Primary outcome [1] 259226 0
To show that the average time patients receive therapeutic warfarin dosing, is at least 25% lower than the average time patients treated with enoxaparin spend in therapeutic range. Time in therapeutic range for warfarin group will be calculated from INR results using Rosendaals' linear interpolation method. In the enoxaparin group therapeutic treatment will be measured by determining the number of missed doses of study drug as recorded in patient diaries and records of the number of pre-filled syringes used. An anti-factor Xa test will be conducted on day 14 (4 hours post injection time) to confirm that the treatment dose results in therapeutic anti-coagulation in that individual.
Timepoint [1] 259226 0
Within the first six weeks of treatment
Secondary outcome [1] 265631 0
To investigate patient expectations and satisfaction with enoxaparin compared with standard warfarin treatment using the PACT-Q (Perception of Anticoagulant Treatment Questionnaires).
Timepoint [1] 265631 0
After the first six weeks of treatment
Secondary outcome [2] 265632 0
To compare the cost of treating a calf Deep Vein Thrombosis (DVT) with enoxaparin than costs associated with warfarin including drug costs, laboratory costing and health care professional time. Resource utilization will be estimated by way of hospital records and patient diaries for both treatment groups. Resource data to be targeted will include doctor visits, drug costs and drug administration costs eg nurse visits, laboratory tests. Adverse reaction (e.g. recurrent Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), bleeding event or post thrombotic syndrome) incidence and treatment costs will also be estimated. Hospital and government information sources will be accessed.
Timepoint [2] 265632 0
Throughout the first six weeks of treatment
Secondary outcome [3] 265633 0
To explore whether enoxaparin is as effective as warfarin in terms of clot resolution and bleeding events. A follow up ultrasound will be conducted at the week 6 visit unless symptomatic recurrence has occurred prior to 6 week visit. Recurrent VTE is defined as a thrombus in the contralateral leg, another deep vein of the same leg, or in the same venous system with a proximal extension of at least 5 cm above the original thrombus. Changes on ultrasounds from baseline will be rated by an independent blinded adjudicator. In addition patients will be asked to report any worsening signs or symptoms of Venous Thromboembolism (eg leg swelling or pain, shortness of breath etc.) up to 12 weeks after randomisation.
Timepoint [3] 265633 0
During the first six weeks of treatment

Eligibility
Key inclusion criteria
Consenting adult patients with symptomatic isolated calf vein (infra-popliteal) DVT as demonstrated with a positive ultrasound.
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Pregnancy and breast feeding
2. Associated pulmonary embolism (PE) or proximal DVT
3. Known hypersensitivity to heparin
4. Thrombocytopenia (baseline platelets less than 50x10 9L)
5. Impaired renal function (baseline eGFR less than 30)
6. Presence of active bleeding or a pathology susceptible to bleeding in the presence of anticoagulant
7. Significant Liver Disease (baseline INR greater than 1.5)
8. Treatment with warfarin is contraindicated
9. Active malignancy
10. Inability or unwillingness of patients to complete English questionnaires or maintain a diary
11. Necessity to receive anticoagulants for an indication other than calf vein thrombosis

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 4
Type of endpoint/s
Pharmacodynamics
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Date of first participant enrolment
Anticipated
18/06/2010
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
86
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment postcode(s) [1] 3258 0
2010
Recruitment postcode(s) [2] 3259 0
2033
Recruitment postcode(s) [3] 3260 0
2217

Funding & Sponsors
Funding source category [1] 257668 0
Self funded/Unfunded
Name [1] 257668 0
Country [1] 257668 0
Primary sponsor type
University
Name
University of New South Wales
Address
UNSW
High St
Kensington
NSW
2033
Country
Australia
Secondary sponsor category [1] 256885 0
None
Name [1] 256885 0
Address [1] 256885 0
Country [1] 256885 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 259689 0
St Vincent's Hospital Human Research Ethics Committee (HREC)
Ethics committee address [1] 259689 0
Ethics committee country [1] 259689 0
Australia
Date submitted for ethics approval [1] 259689 0
Approval date [1] 259689 0
22/03/2010
Ethics approval number [1] 259689 0
HREC/10/SVH/3

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 31655 0
Address 31655 0
Country 31655 0
Phone 31655 0
Fax 31655 0
Email 31655 0
Contact person for public queries
Name 14902 0
Dr Nicola Chapman
Address 14902 0
St George Clinical School
Level 2, WR Pitney Clinical Sciences Building
St George Hospital
Gray St
Kogarah
NSW
2217
Country 14902 0
Australia
Phone 14902 0
+61 2 9113 2582
Fax 14902 0
Email 14902 0
[email protected]
Contact person for scientific queries
Name 5830 0
Dr Nicola Chapman
Address 5830 0
St George Clinical School
Level 2, WR Pitney Clinical Sciences Building
St George Hospital
Gray St
Kogarah
NSW
2217
Country 5830 0
Australia
Phone 5830 0
+61 2 9113 2582
Fax 5830 0
Email 5830 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.